Raven biotechnologies advances RAV18 through agreement with CMC ICOS Biologics Inc.
12-Mar-2008
By:Kevin Egan
South San Francisco, CA and Seattle, WA. March 12 2008.
Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer and CMC ICOS Biologics, Inc. a leading contract manufacturing organization, today announced they have entered into an agreement under which CMC ICOS will create a production cell line for Raven’s next IND candidate, RAV18.
Read the entire pdf press release.
